Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00256750
Show Display Options
Rank Status Study
1 Active, not recruiting Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
Conditions: Kidney Transplantation;   Chronic Kidney Failure
Interventions: Drug: CsA;   Drug: Belatacept LI;   Drug: Belatacept MI

Indicates status has not been verified in more than two years